• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Introduction to 2,3-Dichloro-6-iodoquinoline (CAS No. 1447959-18-3)

2,3-Dichloro-6-iodoquinoline, with the chemical formula C?H?Cl?IN?, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinoline family, a class of molecules known for their diverse biological activities and utility in drug development. The presence of both chlorine and iodine substituents on the quinoline core enhances its reactivity, making it a valuable intermediate in synthetic chemistry and a promising candidate for further exploration in medicinal applications.

The CAS number 1447959-18-3 uniquely identifies this compound in scientific literature and databases, facilitating its accurate classification and retrieval of related research. 2,3-Dichloro-6-iodoquinoline exhibits a unique structural framework that positions it as a versatile building block for the synthesis of more complex molecules. Its halogenated structure allows for further functionalization through cross-coupling reactions, such as Suzuki-Miyaura or Stille couplings, which are widely employed in the construction of biaryl systems found in many active pharmaceutical ingredients (APIs).

In recent years, quinoline derivatives have been extensively studied due to their broad spectrum of biological activities. Among these, 2,3-dichloro-6-iodoquinoline has shown particular promise in the development of novel therapeutic agents. Its ability to act as a precursor for more sophisticated molecules has made it a focus of interest in academic and industrial research laboratories. The compound’s dual halogenation provides multiple sites for selective modification, enabling the creation of structurally diverse derivatives with tailored pharmacological properties.

One of the most compelling aspects of 2,3-dichloro-6-iodoquinoline is its role in the synthesis of antimalarial and anticancer agents. Quinoline-based compounds have a long history of use in treating parasitic infections, with chloroquine being a well-known example. The introduction of additional functional groups through modifications like chlorination and iodination enhances the binding affinity and efficacy of these derivatives against target enzymes or receptors. Current research is exploring how structural variations influenced by 2,3-dichloro-6-iodoquinoline can lead to more effective treatments against drug-resistant strains of pathogens.

Moreover, the iodine atom in 2,3-dichloro-6-iodoquinoline serves as an excellent handle for radio labeling studies, which are crucial for understanding metabolic pathways and pharmacokinetic behavior. Radiolabeled compounds are frequently used in positron emission tomography (PET) scans to visualize biological processes non-invasively. The versatility of this compound allows researchers to incorporate radioactive isotopes at specific positions while maintaining overall structural integrity, providing insights into drug distribution and action within living systems.

The synthetic pathways involving 2,3-dichloro-6-iodoquinoline are also worth mentioning. The compound can be synthesized through multi-step organic transformations that often begin with commercially available quinoline precursors. For instance, selective halogenation techniques such as electrophilic aromatic substitution can be employed to introduce chlorine atoms at the 2 and 3 positions. Subsequent iodination can then be achieved using reagents like N-Iodosuccinimide (NIS) or molecular iodine under controlled conditions. These synthetic strategies highlight the compound’s accessibility and utility in laboratory settings.

In addition to its pharmaceutical applications, 2,3-dichloro-6-iodoquinoline has found utility in materials science and agrochemical research. Its ability to participate in various chemical reactions makes it a valuable intermediate for developing dyes, pigments, and specialty chemicals. Researchers are exploring its potential use in creating novel materials with enhanced electronic properties or improved stability under environmental stressors. Such applications underscore the broad utility of this compound beyond traditional medicinal chemistry.

The latest advancements in computational chemistry have further accelerated the study of 2,3-dichloro-6-iodoquinoline by enabling high-throughput virtual screening and molecular modeling studies. These computational approaches allow researchers to predict binding affinities, metabolic stability, and potential side effects before conducting expensive wet-lab experiments. By integrating experimental data with computational insights, scientists can optimize derivatives derived from 2,3-dichloro-6-iodoquinoline more efficiently than ever before.

Future directions in research on 2,3-dichloro-6-iodoquinoline may include exploring its role in addressing emerging infectious diseases and developing next-generation antiviral agents. The ongoing global health challenges underscore the need for innovative therapeutic strategies that leverage existing scaffolds like quinolines to combat new pathogens effectively. Collaborative efforts between academia and industry are essential to translate laboratory findings into clinical applications that benefit society.

In conclusion,2,3-Dichloro-6-iodoquinoline (CAS No. 1447959-18-3) is a multifaceted compound with significant potential across multiple domains of chemical research and application. Its unique structural features make it an invaluable tool for synthesizing complex molecules with diverse biological activities. As our understanding of its properties continues to grow through innovative research methodologies,2,3-dichloro-6-iodoquinoline is poised to play an increasingly important role in addressing some of today’s most pressing scientific challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)